Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 728 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenocarcinoma of the Prostate Clear all
Completed Phase 2 Interventional

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

NCT00096499
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ispinesib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 1 Interventional

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

NCT02458716
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Prostate Carcinoma Metastatic to the Bone
Interventions
Robotic Assisted Radical Prostatectomy, Conventional open retropubic radical prostectomy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Procedure · Other · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Duarte, California • Orange, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 3 Interventional Results available

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

NCT01546987
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH agonist, Anti-androgen, TAK-700, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 3 Interventional Results available

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

NCT00004124
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, goserelin, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
234
States / cities
Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 157 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Nov 14, 2026, 9:41 PM EST
Terminated Phase 2 Interventional Results available

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

NCT02168062
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
Behavioral · Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Nov 14, 2026, 9:41 PM EST
Recruiting Phase 2 Interventional

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
Procedure · Drug · Other + 1 more
Lead sponsor
Sean Sachdev
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 2 Interventional

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

NCT00002889
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin, leuprolide acetate, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
30 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Nov 14, 2026, 9:41 PM EST
Withdrawn Phase 2 Interventional

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04781374
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic
Interventions
Neratinib
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Nov 14, 2026, 9:41 PM EST
Completed No phase listed Observational

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

NCT02981797
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Blood Collection During Standard of Care Treatment
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Nov 14, 2026, 9:41 PM EST
Recruiting Phase 1 Interventional

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions
Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
1,394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Active, not recruiting Phase 2 Interventional

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Recruiting Phase 2 Interventional

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

NCT07025369
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Completed Not applicable Interventional

A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence

NCT05735223
View directory record Official record
Conditions
Prostate Adenocarcinoma, Incontinence Stress, Erectile Dysfunction Following Radical Prostatectomy
Interventions
Maximal urethral length preservation technique of robot assisted radical prostatectomy (RALP).
Procedure
Lead sponsor
Larkin Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Nov 14, 2026, 9:41 PM EST
Completed Not applicable Interventional Results available

Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)

NCT01856855
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
Interventions
Stereotactic Body Radiation Therapy with Integrated Boost
Radiation
Lead sponsor
John Fiveash, MD
Other
Eligibility
19 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Nov 14, 2026, 9:41 PM EST
Terminated Phase 2 Interventional Results available

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

NCT03999515
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Enzalutamide, Erdafitinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 14, 2026, 9:41 PM EST
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NCT04513717
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
594
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00109811
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 1Phase 2 Interventional

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

NCT05864144
View directory record Official record
Conditions
Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions
SNS-101 (anti-VISTA), Cemiplimab
Drug
Lead sponsor
Sensei Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 2 Interventional Results available

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

NCT04743934
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Flibanserin 100 MG, Placebo, Androgen deprivation therapy
Drug
Lead sponsor
Andrew McDonald
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Completed Not applicable Interventional Results available

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer

NCT00706966
View directory record Official record
Conditions
Nonmalignant Neoplasm, Prostate Cancer
Interventions
dutasteride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Nov 14, 2026, 9:41 PM EST
Terminated Phase 1Phase 2 Interventional

To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer

NCT04843319
View directory record Official record
Conditions
Advanced Prostate Adenocarcinoma
Interventions
VERU-100
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Tucson, Arizona • San Bernardino, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Nov 14, 2026, 9:41 PM EST
Active, not recruiting Phase 2 Interventional

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NCT04777071
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 14, 2026, 9:41 PM EST
Completed Phase 2 Interventional Results available

Enzalutamide in Patients With High-risk Prostate Cancer

NCT01927627
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
enzalutamide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Nov 14, 2026, 9:41 PM EST
Recruiting Phase 2 Interventional

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

NCT04734730
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 14, 2026, 9:41 PM EST